Floatz logo

Sirolimus

Prostate Cancer

Medical University of South CarolinaSmall moleculePhase 2/3Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
59/ 100

Competitive context

481 Active assets in the Prostate Cancer cohort.

Asset / SponsorPhaseRating
Avodart
Bay State Clinical Trials, Inc.
Phase 4BBB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
PROPOFOL
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
Degarelix
Bayer
Phase 4BBB
FLOTUFOLASTAT F 18
Washington University School of Medicine
Phase 4BB

View all 50 →

Same molecule, other indications

Sirolimus is also rated in:

tuberous sclerosisActive
BBB
Indicative · Phase 3
73 / 100
View asset →
disease related to transplantationDormant
BBB
Indicative · Phase 4
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmActive
BB
Indicative · Phase 2
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →